Results have shown that some HR-deficient cancers have an enhanced response to PARP inhibitors as well as to platinum-based chemotherapies; thus it has been concluded that HRD can be considered a biomarker for the responses of these drugs [41]. The gene discussed is PARP1; the disease is cancer.